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To peel or not to peel the internal
limiting membrane: a question
finally answered?
David Wong
For the surgical treatment of idiopathic
thickness macular hole, the question of
whether to peel or not to peel the internal
limiting membrane (ILM) has been asked
repeatedly since at least 2002.1 2 Most
surgeons carry out ILM peeling routinely.
Many are already convinced of its benefit.
Is it worthwhile conducting a randomised
trial when the clinical practice of ILM peel
has already been widely adopted? Is the
answer simply academic?
If all macular holes respond in the same
way to surgery, the answer might indeed
be academic. They do not. It is now clear
that smaller holes close more readily.3 A
lesser intervention may be appropriate for
the treatment of smaller holes. For exam-
ple, a recent randomised trial comparing a
facedown versus a seated position found
that the success rate in idiopathic macular
holes smaller than 400 mm was not
influenced by postoperative posture.4
On the other hand, if the maximum
intervention works best, why not apply it
to every patient? After all, there is a price
to pay for failure in primary closure. Holes
that do not close after the first vitrectomy
tend to increase in size, and even when
they are closed with a repeat operation,
the visual results are often poor.5 The
point is that the maximum algorithm has
its drawbacks. The use of long-acting
gases and head-down posture may simply
be inconvenient for patients. ILM peeling
and preretinal manipulations may impor-
tantly be associated with retinal pigment
epithelial changes,6 trauma to the neuro-
sensory retina, phototoxicity resulting
from prolonged manipulations and possi-
ble adverse reactions to the dyes used.7
In this issue (see page 1005),
Christensen carried out a randomised con-
trolled trial of no peel versus peel using
Indocyanine Green (ICG) in a single centre,
Glostrup Hospital in Denmark.8 This well-
conducted study aimed at examining the
value of ILM peeling in stage-2 and -3
idiopathic macular hole surgery. The
results show that surgery with ILM peel-
ing, for both stage 2 and -3 macular hole, is
associated with a significantly higher clo-
sure rate than surgery without ILM peeling
(stage 2: 100% vs 55%; stage 3: 90% vs
36%). The results seem convincing.
Does this mean that the question is
now finally answered? Yes and no. There
may still be room for doubt, given that
randomisation was changed after 40
patients were recruited. The interim
analysis of stage 3 holes showed that the
peeled group did significantly better. The
stopping rule for randomisation meant
that it was unethical to continue. For the
remainder of the trial, the patients with
stage 3 holes were randomised 2:1 to ILM
peeling with Trypan Blue (TB) or ICG.
The randomisation to no peeling stopped
after 14 stage 3 holes were recruited
(presumably because nine holes failed to,
as the anatomical success rate in this
group was 36%). Is this a representative
result, or is it a statistical quirk due to
clustering of failures? Brooks, in a non-
randomised study, achieved with no ILM
peeling an anatomical success rate of
82%;9 Margherio et al, in a consecutive
study, achieved with no ILM peeling an
anatomical closure rate of 86%.10
The majority of the patients (.80%) in
this Danish trial were rendered pseudo-
phakic 4 weeks prior to the vitrectomy.
This was done in order to eliminate one of
the major confounding factors that
dogged many previous studies on macular
hole surgery, namely progressive lens
opacity following vitrectomy affecting
the visual outcome. However, could the
cataract surgery have contributed to the
unusually low anatomical success rate of
non-peeling group? A recent study on
patients who had cataract surgery before,
after or combined with vitrectomy and
vitrectomy alone for idiopathic macular
hole found that cystoid macular oedema
was associated with a sevenfold increase
in reopening of the closed macular holes.11
There is a high incidence of cystoid
macular oedema following cataract sur-
gery, the majority being subclinical.12
Equally, ILM peeling is a recognised
treatment for cystoid macular oedema in
conditions such as diabetic retinopathy
and retinal vein occlusion.13 14 Is it con-
ceivable that by rendering the patients
pseudophakic prior to the vitrectomy, the
trial favoured ILM peeling and disadvan-
taged the no-peeling group?
What started off as a study to address
primarily a single research question,
namely, ‘‘Is peeling better than no peel-
ing?’’, effectively became a three-arm trial
of no dye (and no peel) versus ICG-
assisted peeling versus TB-assisted peel-
ing. Nonetheless, the information yielded
by the second randomisation is both
interesting and relevant. The study con-
cluded that ‘‘intraoperative ILM staining
with 0.05% isotonic ICG was not asso-
ciated with a significantly different visual
outcome than non-peeling or TB peeling
in eyes with primary hole closure.’’ One of
the many strengths of this study was the
recording of postoperative visual fields in
all patients. A visual-field defect occurred
in one of 35 patients treated with ICG,
one of 18 patients with TB and none with
non-peeling. Those surgeons who use ICG
routinely might take comfort from the
results of this trial and conclude that ICG
at a concentration of 0.05% is safe.
Equally, those who have experienced
unexplained visual-field loss following
ICG-assisted peel might believe that the
adverse reaction to this dye is idiosyn-
cratic and as such not likely to be detected
in a relatively small number of patients.
There is still variation in our approaches
to the treatment of idiopathic macular
hole. There are those surgeons who do no
peeling, those who peel but use no dye,
those who use ICG-assisted peel and yet
others who are switching to the newer and
purported ‘‘safer’’ dyes.15 It is fair to say
that the majority are already persuaded by
the efficacy of ILM peeling, and
Christensen et al through their meticulous
study will convince even more surgeons to
peel routinely. It is noteworthy that the
only other randomised trial of vitrectomy
with or without ILM peeling of for
idiopathic macular hole in Chinese patients
found a very similar anatomical closure rate
of 92% and 32% respectively.16 There is a
UK multicentre randomised trial of ILM
peel versus no peel that has finished
recruiting.17 (FILMS is registered with
Current Controlled Trials ISRCTN num-
ber 33175422 and Clinical Trials.gov iden-
tifier NCT00286507.) It would be
interesting to see if the British results
corroborated that of the Danish trial.
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